Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication

Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication

Abstract Epidermal growth factor receptor (EGFR) kinase domain duplication (KDD) has been identified as an oncogenic driver in 0.05% to 0.14% of non–small cell lung cancer (NSCLC) patients. However, little is known of the efficacy of EGFR tyrosine kinase inhibitors (TKIs) for such patients. Here, we...

Full description

Bibliographic Details
Main Authors: Esuteru Hirokawa, Satomi Watanabe, Kazuko Sakai, Masayuki Takeda, Chihiro Sato, Takayuki Takahama, Kazuto Nishio, Kazuhiko Nakagawa
Format: Article
Language:English
Published: Wiley 2021-08-01
Series:Thoracic Cancer
Subjects:
carcinomatous meningitis
epidermal growth factor receptor (EGFR)
kinase domain duplication
tyrosine kinase inhibitor (TKI)
Online Access:https://doi.org/10.1111/1759-7714.14081

Internet

https://doi.org/10.1111/1759-7714.14081

Similar Items